Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC) has granted stock options to two new employees as part of their inducement compensation package. The grants, made under the company's 2022 Inducement Stock Incentive Plan, include a total of 260,000 options to purchase common stock at an exercise price of $5.73 per share, matching the closing price on May 5, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. Vesting is contingent on continued employment with Fulcrum through the applicable dates.

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees an aggregate of 260,000 options to purchase shares of the company’s common stock at an exercise price of $5.73 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, May 5, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What stock options did Fulcrum Therapeutics (FULC) grant to new employees in May 2025?

Fulcrum granted 260,000 stock options to two new employees at an exercise price of $5.73 per share, with a ten-year term and four-year vesting schedule.

What is the vesting schedule for FULC's May 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and 6.25% vesting quarterly over the following twelve quarters.

What was the exercise price for Fulcrum Therapeutics' May 2025 employee stock options?

The exercise price was $5.73 per share, matching Fulcrum's closing stock price on May 5, 2025.

Under which plan did Fulcrum (FULC) grant the May 2025 employee stock options?

The options were granted under Fulcrum's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).